We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Cantargia AB (CANTA) NPV

Sell:18.52 SEK Buy:18.59 SEK Change: 1.08 SEK (6.16%)
Market closed |  Prices as at close on 26 November 2021 | Switch to live prices |
Sell:18.52 SEK
Buy:18.59 SEK
Change: 1.08 SEK (6.16%)
Market closed |  Prices as at close on 26 November 2021 | Switch to live prices |
Sell:18.52 SEK
Buy:18.59 SEK
Change: 1.08 SEK (6.16%)
Market closed |  Prices as at close on 26 November 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.

Contact details

Address:
Scheelevagen 27
LUND
223 63
Sweden
Telephone:
+46 (46) 2756260
Website:
www.cantargia.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CANTA
ISIN:
SE0006371126
Market cap:
1.76 billion SEK
Shares in issue:
100.19 million
Sector:
Biotechnology
Exchange:
Stockholm Stock Exchange
Country:
Sweden
Currency:
Swedish Krona
Indices:
n/a

Key personnel

  • Magnus Persson
    Chairman of the Board
  • Goran Forsberg
    Chief Executive Officer
  • Bengt Jondell
    Chief Financial Officer
  • Liselotte Larsson
    Chief Operating Officer
  • Susanne Lagerlund
    Vice President - Regulatory Affairs
  • David Liberg
    Vice President Cancer Research
  • Nedjad Losic
    Vice President - Biometrics
  • Peter Madsen
    Vice President - CMC
  • Lars Thorsson
    Vice President Clinical Development
  • Ignacio Garcia-Ribas
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.